Dashboard
Manage Tickers

MRKMerck & Co., Inc.

NYSE merck.com


$ 118.29 $ 0.33 (0.28 %)    

Tuesday, 17-Sep-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.83 $ 0.25 (0.05 %)
DIA $ 417.12 $ -0.12 (-0.03 %)
SPY $ 563.14 $ 0.23 (0.04 %)
TLT $ 100.82 $ -0.49 (-0.48 %)
GLD $ 237.35 $ -1.32 (-0.55 %)
$ 118.29
$ 118.97
$ 118.28 x 200
$ 122.90 x 500
$ 117.74 - $ 119.03
$ 96.58 - $ 133.74
5,876,393
na
299.84B
$ 0.34
$ 21.83
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 05-03-2024 03-31-2024 10-Q
3 02-26-2024 12-31-2023 10-K
4 11-03-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-05-2023 03-31-2023 10-Q
7 02-24-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-25-2022 12-31-2021 10-K
12 11-05-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-05-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 02-26-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 02-27-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 02-27-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 02-28-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 02-26-2016 12-31-2015 10-K
36 11-05-2015 09-30-2015 10-Q
37 08-06-2015 06-30-2015 10-Q
38 05-07-2015 03-31-2015 10-Q
39 02-27-2015 12-31-2014 10-K
40 11-10-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

competitor-analysis-evaluating-merck-amp-co-and-competitors-in-pharmaceuticals-industry
Competitor Analysis: Evaluating Merck &amp...
09/17/2024 15:00:55

merckdaiichi-sankyo-partnered-lung-cancer-candidate-meets-primary-goal-in-late-stage-study
Merck/Daiichi Sankyo Partnered Lung Cancer...
09/17/2024 11:58:10

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung...

daiichi-sankyo-and-merck-report-patritumab-deruxtecan-showed-statistically-significant-progression-free-survival-improvement-in-egfr-mutated-non-small-cell-lung-cancer-population
Daiichi Sankyo And Merck Report Patritumab...
09/17/2024 10:03:14

The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastaticEGFR-mutated ...

a-closer-look-at-8-analyst-recommendations-for-merck--co
A Closer Look at 8 Analyst Recommendations...
09/16/2024 19:00:44

cantor-fitzgerald-reiterates-overweight-on-merck--co-maintains-155-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/16/2024 16:17:47

Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $155 price target.

nucanas-encouraging-data-from-resistant-melanoma-treatment-provides-some-relief-after-disappointing-colorectal-cancer-data-stock-surges
NuCana's Encouraging Data From Resistant M...
09/16/2024 13:24:13

NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% disea...

Core News & Articles
Immutep's Efti In Combination With MSD's K...
09/16/2024 12:15:18

Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024In patients with any PD-L1 expression (...

Core News & Articles
Reported Saturday, Merck And Eisai's Phase...
09/16/2024 06:36:52

In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or deat...

reported-saturday-mercks-keytruda-plus-chemoradiotherapy-slashes-mortality-risk-by-33-in-patients-with-newly-diagnosed-high-risk-locally-advanced-cervical-cancer
Reported Saturday, Merck's KEYTRUDA Plus C...
09/16/2024 06:31:40

KEYNOTE-A18 is the first Phase 3 study of an immunotherapy in combination with CRT to demonstrate a statistically significant...

reported-saturday-mercks-keytruda-plus-trastuzumab-and-chemotherapy-extends-survival-in-advanced-gastric-cancer-or-gej-adenocarcinoma
Reported Saturday, Merck's KEYTRUDA Plus T...
09/16/2024 06:26:15

KEYTRUDA is the first anti-PD-1/L1 therapy in combination with trastuzumab and chemotherapy to demonstrate a statistically si...

reported-sunday-mercks-keytruda-achieves-sustained-10-year-survival-advantage-over-ipilimumab-in-advanced-melanoma
Reported Sunday, Merck's KEYTRUDA Achieves...
09/16/2024 06:21:27

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared ...

moderna-faces-analyst-downgrades-amid-revised-rd-restructured-strategy-and-delayed-profitability-target
Moderna Faces Analyst Downgrades Amid Revi...
09/13/2024 22:34:46

Moderna announces plans to reduce R&D spending by $1.1 billion by 2027, focusing on ten key products. Analysts highlight ne...

merck--co-unusual-options-activity
Merck & Co Unusual Options Activity
09/13/2024 19:35:43

health-canada-has-approved-mercks-keytruda-pembrolizumab-for-adult-and-pediatric-patients-with-unresectable-or-metastatic-microsatellite-instability-high-or-mismatch-repair-deficient-solid-tumors-progressed-following-prior-treatment-and-who-have-no-satisfactory-alternative-treatment-options
Health Canada Has Approved Merck's Keytrud...
09/12/2024 11:03:30

mercks-gardasil-9-meets-key-endpoints-in-japanese-male-hpv-trial
Merck's GARDASIL 9 Meets Key Endpoints in ...
09/11/2024 10:32:08

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from its pivo...

methanex-merck-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Methanex, Merck And Other Big Stocks Movin...
09/09/2024 12:11:16

summit-therapeutics-lung-cancer-candidate-surpasses-mercks-multi-billion-dollar-keytruda-cuts-risk-of-disease-or-death-by-half
Summit Therapeutics' Lung Cancer Candidate...
09/09/2024 12:02:45

Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free sur...

why-summit-therapeutics-shares-are-trading-higher-by-around-18-here-are-20-stocks-moving-premarket
Why Summit Therapeutics Shares Are Trading...
09/09/2024 10:08:36

Core News & Articles
Reported Saturday, Daiichi Sankyo And Merc...
09/09/2024 08:13:06

Objective response rate of 54.8% seen with Daiichi Sankyo and Merck's ifinatamab deruxtecan at 12 mg/kg dose in pretreate...

whats-going-on-with-merck-shares-thursday
What's Going On With Merck Shares Thursday?
09/05/2024 18:42:49

Merck stock is trading higher on Thursday after the company announced it completed negotiations with the pan-Canadian Pharmaceu...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION